NCT02211833View on ClinicalTrials.gov

Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

February 28, 2009

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

BI 2536

DRUG

Pemetrexed

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY